Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Redmond, William L ^a   Triplett, Todd ^a,b   Floyd, Kevin ^a   Weinberg, Andrew D ^a,b  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; JANUS KINASE 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX40; STAT3 PROTEIN; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; UNCLASSIFIED DRUG; CYTOKINE; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN RECEPTOR; STAT3 PROTEIN, MOUSE; STAT5A PROTEIN, MOUSE; STAT5B PROTEIN, MOUSE; TNFRSF4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; REGULATORY MECHANISM; SARCOMA; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOTOXIC T LYMPHOCYTE; DRUG COMBINATION; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; REGULATORY T LYMPHOCYTE; TUMOR CELL CULTURE; WESTERN BLOTTING;

MUS;

ANIMALS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; JANUS KINASE 3; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, OX40; SARCOMA, EXPERIMENTAL; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED;

EID: 84859354954     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034467     Document Type: Article

References (52)

1. Watts TH, (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23: 23-68.
2. Croft M, (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3: 609-620.
3. Croft M, (2010) Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 28: 57-78.
4. Redmond WL, Ruby CE, Weinberg AD, (2009) The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol 29: 187-201.
5. Taraban VY, Rowley TF, O'Brien L, Chan HT, Haswell LE, et al. (2002) Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol 32: 3617-3627.
6. Gramaglia I, Weinberg AD, Lemon M, Croft M, (1998) Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 161: 6510-6517.
7. Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, Auphan-Anezin N, (2006) STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J Immunol 176: 4834-4842.
8. Walker LS, Gulbranson-Judge A, Flynn S, Brocker T, Raykundalia C, et al. (1999) Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXC chemokine receptor 5-positive CD4 cells and germinal centers. J Exp Med 190: 1115-1122.
9. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M, (2001) OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15: 445-455.
10. Williams CA, Murray SE, Weinberg AD, Parker DC, (2007) OX40-mediated differentiation to effector function requires IL-2 receptor signaling but not CD28, CD40, IL-12Rbeta2, or T-bet. J Immunol 178: 7694-7702.
11. Akiba H, Oshima H, Takeda K, Atsuta M, Nakano H, et al. (1999) CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J Immunol 162: 7058-7066.
12. Lenschow DJ, Walunas TL, Bluestone JA, (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258.
13. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, et al. (2000) The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 165: 3043-3050.
14. Lathrop SK, Huddleston CA, Dullforce PA, Montfort MJ, Weinberg AD, et al. (2004) A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. J Immunol 172: 6735-6743.
15. Evans DE, Prell RA, Thalhofer CJ, Hurwitz AA, Weinberg AD, (2001) Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J Immunol 167: 6804-6811.
16. Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD, (2007) Defects in the Acquisition of CD8 T Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist. J Immunol 179: 7244-7253.
17. Nelson BH, Willerford DM, (1998) Biology of the interleukin-2 receptor. Adv Immunol 70: 1-81.
18. Gaffen SL, (2001) Signaling domains of the interleukin 2 receptor. Cytokine 14: 63-77.
19. Toennies HM, Green JM, Arch RH, (2004) Expression of CD30 and Ox40 on T lymphocyte subsets is controlled by distinct regulatory mechanisms. J Leukoc Biol 75: 350-357.
20. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, et al. (2001) Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 1: 4.
21. Spiess PJ, Yang JC, Rosenberg SA, (1987) In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 79: 1067-1075.
22. Kovanen PE, Leonard WJ, (2004) Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev 202: 67-83.
23. Rochman Y, Spolski R, Leonard WJ, (2009) New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9: 480-490.
24. Changelian PS, Moshinsky D, Kuhn CF, Flanagan ME, Munchhof MJ, et al. (2008) The specificity of JAK3 kinase inhibitors. Blood 111: 2155-2157.
25. Leonard WJ, O'Shea JJ, (1998) Jaks and STATs: biological implications. Annu Rev Immunol 16: 293-322.
26. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J, (2006) Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311: 1924-1927.
27. Krieg C, Letourneau S, Pantaleo G, Boyman O, (2010) Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 107: 11906-11911.
28. Klinger M, Kim JK, Chmura SA, Barczak A, Erle DJ, et al. (2009) Thymic OX40 expression discriminates cells undergoing strong responses to selection ligands. J Immunol 182: 4581-4589.
29. Rabinovich GA, Gabrilovich D, Sotomayor EM, (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296.
30. Lees JR, Charbonneau B, Swanson AK, Jensen R, Zhang J, et al. (2006) Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells. Immunology 117: 248-261.
31. Redmond WL, Gough MJ, Weinberg AD, (2009) Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol 39: 2184-2194.
32. Sarkar S, Kalia V, Haining WN, Konieczny BT, Subramaniam S, et al. (2008) Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med 205: 625-640.
33. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, et al. (2007) Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27: 281-295.
34. Takeda I, Ine S, Killeen N, Ndhlovu LC, Murata K, et al. (2004) Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 172: 3580-3589.
35. Shimoda M, Mmanywa F, Joshi SK, Li T, Miyake K, et al. (2006) Conditional ablation of MHC-II suggests an indirect role for MHC-II in regulatory CD4 T cell maintenance. J Immunol 176: 6503-6511.
36. Kish DD, Gorbachev AV, Fairchild RL, (2007) Regulatory function of CD4+CD25+ T cells from Class II MHC-deficient mice in contact hypersensitivity responses. J Leukoc Biol 82: 85-92.
37. Piconese S, Pittoni P, Burocchi A, Gorzanelli A, Care A, et al. (2010) A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2. Eur J Immunol 40: 2902-2913.
38. Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, et al. (2009) Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30: 80-91.
39. Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, et al. (2004) IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 173: 900-909.
40. Gadina M, Sudarshan C, Visconti R, Zhou YJ, Gu H, et al. (2000) The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. J Biol Chem 275: 26959-26966.
41. Basham B, Sathe M, Grein J, McClanahan T, D'Andrea A, et al. (2008) In vivo identification of novel STAT5 target genes. Nucleic Acids Res 36: 3802-3818.
42. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, et al. (1998) Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93: 841-850.
43. John S, Vinkemeier U, Soldaini E, Darnell JE Jr, Leonard WJ, (1999) The significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol 19: 1910-1918.
44. Yu CR, Young HA, Ortaldo JR, (1998) Characterization of cytokine differential induction of STAT complexes in primary human T and NK cells. J Leukoc Biol 64: 245-258.
45. Tone Y, Kojima Y, Furuuchi K, Brady M, Yashiro-Ohtani Y, et al. (2007) OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-kappa B binding sites. J Immunol 179: 1760-1767.
46. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, et al. (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164: 2160-2169.
47. Xiao X, Gong W, Demirci G, Liu W, Spoerl S, et al. (2012) New Insights on OX40 in the Control of T Cell Immunity and Immune Tolerance In Vivo. J Immunol 188: 892-901.
48. Niedbala W, Cai B, Liu H, Pitman N, Chang L, et al. (2007) Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40. Proc Natl Acad Sci U S A 104: 15478-15483.
49. Kitamura N, Murata S, Ueki T, Mekata E, Reilly RT, et al. (2009) OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity. Int J Cancer 125: 630-638.
50. Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, et al. (2009) In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 206: 751-760.
51. Verdeil G, Marquardt K, Surh CD, Sherman LA, (2008) Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci U S A.
52. Kamimura D, Bevan MJ, (2007) Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med 204: 1803-1812.